RELA and liver cancer: In this study, we propose the potential for rational use of the RELA agonist BetA in personalized therapeutic strategies against liver cancer, particularly in TP53R249S‐mutated HepG2 and Huh‐7 tumors that benefited from BetA administration (Figure 7; Figure S11, Supporting Information).